Article

Hypothyroidism

Dr. Jay Cohen, an endocrinologist, discusses thyroid disease. He reviews the difference between hypo and hyper thyroidism, as well as the treatment of hypothryoidism. Memphis, Tenn. Call 901-763-3636 for more information.

Dr. Jay Cohen, an endocrinologist, discusses thyroid disease. He reviews the difference between hypo and hyper thyroidism, as well as the treatment of hypothryoidism. Memphis, Tenn. Call 901-763-3636 for more information.

Related Videos
Advocating for Race-Neutral Approach to Pulmonary Function Testing with Meredith McCormack, MD, and Loretta Que, MD
Gregory Mattingly, MD I St. Charles Psychiatric Associates
Duloxetine for Patients with COPD Suffering from Comorbid Depression
Enhancing Standards for Ethical Responsibilities within Clinical Research
Jennifer Flemming, MD | Credit: AASLD
Related Content
FDA black and white logo | Credit: US Food and Drug Administration
January 28th 2025

FDA Approves Semaglutide (Ozempic) for Type 2 Diabetes, Chronic Kidney Disease

Abigail Brooks, MA
Diabetes Dialogue: ADA’s 2025 Standards of Care in Diabetes Therapeutics| Image Credit: HCPLive
January 23rd 2025

Diabetes Dialogue: ADA’s 2025 Standards of Care in Diabetes Therapeutics

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES Natalie Bellini, DNP, FNP-BC, BC-ADM, CDCE
Thyroid Cancer Diagnoses Rise in First Year of GLP-1 RA Use | Image Credit: University of Maryland
January 24th 2025

Thyroid Cancer Diagnoses Rise in First Year of GLP-1 RA Use

Connor Iapoce
Diabetes Dialogue: ADA’s 2025 Standards of Care in Diabetes | Image Credit: HCPLive
January 16th 2025

Diabetes Dialogue: ADA’s 2025 Standards of Care in Diabetes Technology

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES Natalie Bellini, DNP, FNP-BC, BC-ADM, CDCE
Patient Factors Influence Semaglutide Initiation After Obesity Diagnosis | Image Credit: Boston University
January 21st 2025

Patient Factors Influence Semaglutide Initiation After Obesity Diagnosis

Connor Iapoce
Semaglutide 7.2 mg Exhibits 20.7% Weight Loss in Phase 3b STEP UP Trial | Image Credit: Novo Nordisk
January 17th 2025

Semaglutide 7.2 mg Displays 20.7% Weight Loss in Phase 3b STEP UP Trial

Connor Iapoce
© 2025 MJH Life Sciences

All rights reserved.